Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
04 Outubro 2023 - 5:05PM
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage
oncology company developing targeted therapies for RAS-addicted
cancers, today announced the company will present new clinical data
for two of its RAS(ON) Inhibitors and other investigational
compounds at upcoming oncology conferences, the 2023 AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer
Therapeutics (“Triple Meeting”) in Boston, Massachusetts, to be
held October 11-15, and the 2023 European Society for Medical
Oncology Congress (ESMO) in Madrid, Spain, to be held October
20-24.
At the Triple Meeting, the company will present the
first report of clinical activity for RMC-6291, its RASG12C(ON)
Inhibitor and additional preliminary safety and pharmacokinetic
profiles for RMC-6236, its RASMULTI(ON) Inhibitor. At ESMO, the
company will present additional preliminary antitumor activity data
for RMC-6236 in patients with non-small cell lung cancer (NSCLC) or
pancreatic ductal adenocarcinoma (PDAC) carrying common KRASG12X
mutations. The abstract related to this presentation, which will go
live on the ESMO website at 0:05 CEST on October 16, 2023 (6:05
p.m. ET, October 15), will include data from an April 24, 2023 data
extraction, while the Proffered Paper presentation itself will
include more recent data from an October data extraction.
Shortly following the company’s ESMO data
presentation, the company will host an investor webcast to review
the clinical data presentations on RMC-6236 and RMC-6291, related
clinical development vision, and the company’s overall pipeline and
strategy.
Details of the presentations referenced above, as
well as other presentations by the company at these conferences,
are listed below:
Triple Meeting Oral
Presentations:
Title: |
Targeting RAS-addicted cancers with investigational RAS(ON)
inhibitors |
Presenter: |
W. Clay Gustafson, M.D. |
Session: |
Plenary Session 3: KRAS |
Date/Time: |
8:00 – 9:40 a.m. ET on October
13, 2023 |
|
|
Title: |
Preliminary safety and pharmacokinetic profiles of
RMC-6236, a first-in-class, RAS-selective,
tri-complex RASMULTI(ON)
inhibitor in patients with KRAS mutant solid
tumors on the Phase 1 trial RMC-6236-001 |
Presenter: |
Alexander I. Spira |
Abstract
Number: |
B032* |
Session: |
Plenary Session 4: New Drugs on
the Horizon |
Date/Time: |
9:40 – 11:45 a.m. ET on October
13, 2023 |
*Also included in Poster Session B on October 13,
from 12:30 to 4:00 p.m. ET.
Title: |
Preliminary safety and anti-tumor activity of RMC-6291, a
first-in-class,
tri-complexKRASG12C
(ON) inhibitor, in patients with or without prior
KRASG12C (OFF)
inhibitortreatment |
Presenter: |
Pasi A. Jänne |
Abstract
Number: |
LB_B01* |
Session: |
Spotlight on Proffered Papers
2 |
Date/Time: |
11:50 a.m. – 12:20 p.m. ET on
October 13, 2023 |
*Also included in Poster Session B on October 13,
from 12:30 to 4:00 p.m. ET.
Triple Meeting Poster
Presentations:
Title: |
Selective inhibition of the active state of
KRASG12V with the non-covalent,
tri-complexInhibitor RM-048 |
Presenter: |
Bianca J. Lee, Ph.D. |
Abstract
Number: |
B137 |
Session: |
Poster Session B |
Date/Time: |
12:30 – 4:00 p.m. ET on October
13, 2023 |
|
|
Title: |
First-in-human phase 1/1b trial of the first-in-class
bi-steric mTORC1-selective inhibitor RMC-5552 in patients with
advanced solid tumors |
Presenter: |
Alison M. Schram, M.D. |
Abstract
Number: |
C020 |
Session: |
Poster Session C |
Date/Time: |
12:30 – 4:00 p.m. ET on October
14, 2023 |
|
|
Additional information on the Triple Meeting is
available through the conference website at:
https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2/
ESMO Oral Presentation:
Title: |
Preliminary clinical activity of RMC-6236, a
first-in-class, RAS-selective, tri-complex
RASMULTI(ON) inhibitor in
patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC)
and non-small cell lung cancer (NSCLC) |
Presenter: |
Kathryn C. Arbour, M.D. |
Abstract
Number: |
6520 |
Session: |
Proffered Paper Session –
Developmental Therapeutics |
Date/Time: |
08:30 – 10:00 a.m. CEST (2:30 –
4:00 a.m. ET) on October 22, 2023 |
|
|
Additional information on the ESMO Congress is
available through the conference website at:
https://www.esmo.org/meeting-calendar/esmo-congress-2023.
Investor WebcastRevolution
Medicines will host an investor webcast on Sunday, October 22,
2023, at 12:30 p.m. ET. The presentation will review the clinical
data presentations on RMC-6236 and RMC-6291 highlighted above,
related clinical development vision, and the company’s overall
pipeline and strategy. To participate in the live webcast,
participants may register in advance here:
https://edge.media-server.com/mmc/p/eb8agxe6. A
live webcast of the call will also be available on the Investors
section of Revolution Medicines’ website at
https://ir.revmed.com/events-and-presentations. Following the live
webcast, a replay will be available on the company’s website for at
least 14 days.
About Revolution Medicines,
Inc.
Revolution Medicines is a clinical-stage oncology
company developing novel targeted therapies for RAS-addicted
cancers. The company’s R&D pipeline comprises RAS(ON)
Inhibitors designed to suppress diverse oncogenic variants of RAS
proteins, and RAS Companion Inhibitors for use in combination
treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236
(RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) are
currently in clinical development. Additional RAS(ON) Inhibitors in
the company’s pipeline include RMC-0708 (KRASQ61H) which is
currently in IND-enabling development, RMC-8839 (KRASG13C), and
additional compounds targeting other RAS variants. RAS Companion
Inhibitors in clinical development include RMC-4630 (SHP2) and
RMC-5552 (mTORC1/4EBP1).
Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act
of 1995. Any statements in this press release that are not
historical facts may be considered "forward-looking statements,"
including without limitation statements regarding the company’s
development plans and timelines and its ability to advance its
portfolio and R&D pipeline; clinical data from its RAS(ON)
inhibitors and investigational compounds; its clinical development
vision; and its overall pipeline and strategy. Forward-looking
statements are typically, but not always, identified by the use of
words such as "may," "will," "would," "believe," "intend," "plan,"
"anticipate," "estimate," "expect," and other similar terminology
indicating future results. Such forward-looking statements are
subject to substantial risks and uncertainties that could cause the
company’s development programs, future results, performance, or
achievements to differ materially from those anticipated in the
forward-looking statements. Such risks and uncertainties include
without limitation risks and uncertainties inherent in the drug
development process, including the company’s programs’ early stage
of development, the process of designing and conducting preclinical
and clinical trials, the regulatory approval processes, the timing
of regulatory filings, the challenges associated with manufacturing
drug products, the company’s ability to successfully establish,
protect and defend its intellectual property, other matters that
could affect the sufficiency of the company’s capital resources to
fund operations, reliance on third parties for manufacturing and
development efforts, changes in the competitive landscape and the
effects on the company’s business of the worldwide COVID-19
pandemic. For a further description of the risks and uncertainties
that could cause actual results to differ from those anticipated in
these forward-looking statements, as well as risks relating to the
business of Revolution Medicines in general, see Revolution
Medicines’ Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on August 8, 2023, and its future periodic
reports to be filed with the Securities and Exchange Commission.
Except as required by law, Revolution Medicines undertakes no
obligation to update any forward-looking statements to reflect new
information, events, or circumstances, or to reflect the occurrence
of unanticipated events.
Investor & Media Contact: Erin
Graves650-779-0136egraves@revmed.com
Revolution Medicines (NASDAQ:RVMD)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Revolution Medicines (NASDAQ:RVMD)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024